ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1059

BDCA2 Targeting of Human Plasmacytoid Dendritic Cells via CBS004 Reverts Dependent IFN Activation and Tissue Fibrosis in vitro and in vivo

Rebecca Ross1, Clarissa Corinaldesi 2, Gemma Migneco 3, Yasser El-Sherbiny 4, Steve Holmes 5, Jörg Distler 6, Clive McKimmie 7 and Francesco Del Galdo 8, 1Univesristy of Leeds, Leeds, England, United Kingdom, 2University of Leeds, Leeds, England, United Kingdom, 3University of Leeds, Leeds, United Arab Emirates, 4University of Nottingham, Nottingham, United Kingdom, 5Capella Bioscience, london, United Kingdom, 6Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, Erlangen, Germany, 7University of Leeds, Leeds, United Kingdom, 8University of Leeds and LTHT NIHR Biomedical Research Centre, Leeds, United Kingdom

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: animal models and monoclonal antibodies, interferon, Scleroderma, Skin fibrosis

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Monday, November 11, 2019

Session Title: Systemic Sclerosis & Related Disorders – Basic Science Poster

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Human plasmacytoid dendritic cells (pDCs) have been implicated in the pathogenesis of Systemic Sclerosis (SSc) through their ability to infiltrate the skin and secrete interferons (IFN), interleukin-6 (IL-6) and other proinflammatory chemokines directly, or through type-I IFN response of resident cells. Blood dendritic cell antigen 2 (BDCA-2) is a human-specific pDC-type II C-type lectin that potently inhibits IFN secretion. Here we determined the effects of CBS004, a novel monoclonal antibody against BDCA-2, on Toll-like receptor (TLR)-induced transcriptome

and IFN secretion in pDCs from healthy volunteers (HV) or patients with SSc in vitro, and tested its effect on two different  xeno-transplant mouse models of human pDC dependent tissue inflammation and fibrosis

Methods: Peripheral blood mononuclear cells (PBMCs) were collected from 26 SSc patients and 16 HV. IFN secretion were evaluated by ELISA. TLR7-9 stimulation was induced by Imiquimod or ODN. pDCs were isolated by magnetic cell sorting. Full transcriptome was analysed by RNA-sequencing. For the xenotransplant models,  NOD/SCID mice were injected in the tail vein with 25×104human pDCs, 12 h after topical application of Imiquimod for the inflammation model, and along bleomycin skin injections in the fibrotic model. CBS004 was delivered by intraperitoneal injection at 5 mg/kg. Harvested skin was analysed by FACS for human pDC infiltration, by real-time PCR using a mouse type-I IFN response array (Qiagen) and by histology for dermal thickness.

Results: PBMCs from SSc patients spontaneously produced higher levels of IFN-I compared to HV ex vivo (206.7±23.4 vs. 43.4±6.8 pg/ml, P< 0.0001). CBS004 significantly inhibited basal levels of IFN-I in 83% of SSc samples. TLR9 stimulation of SSc PBMCs induced >30-fold increase in IFN-I secretion (7167±4377 pg/ml), which was completely abrogated by treatment with CBS004 (209±40.5 pg/ml, P< 0.001). RNA-seq analysis of human pDCs stimulated with TLR-9 agonist revealed 168 Differentially Expressed Genes (DEGs, FDR < 1%) mapping to IFN, JAK/STAT, IL-6, NF-kB and angiogenesis pathways. Pretreatment with CBS004 prevented upregulation of most DEGs, which drove an expression profile similar to non-stimulated pDCs. In the xenotransplant model, tail vein injection of pDC resulted in detection of human pDCs in the skin (0.3%) with at least 2-fold upregulation of 35/74 mouse type-I IFN response genes including Ccl2, 4, 5 and Cxcl10, Ifit1, 2 and 3, Mx1 and 2, Oas1, Tlr7, 8 and 9 compared to imiquimod treatment alone (P< 0.005). Mice receiving IP injection of CBS004 had a 3-fold reduction in infiltrating pDCs (0.1%) and suppression of 85% of the type-I IFN response genes upregulated by pDC injection (Anova P< 0.01). In the bleomycin model, pDC injection significantly increased dermal thickness (30%, P< 0.01), which was completely prevented by CBS004 treatment.

Conclusion: Our study demonstrates that BDCA-2 targeting with CBS004 mAb may block both the spontaneous and TLR dependent pDC driven IFN activation in Scleroderma. Further, we show that BDCA2 targeting with CBS004 can revert human pDC driven tissue inflammation and fibrosis in two distinct human pDC xenotransplant mouse models.


Disclosure: R. Ross, None; C. Corinaldesi, None; G. Migneco, None; Y. El-Sherbiny, None; S. Holmes, Capella Biosciences, 3; J. Distler, 4D Science, 4, Actelion, 5, Actelion Pharmaceuticals, 5, Active Biotech, 2, 5, AnaMar, 2, 5, Array Biopharma, 2, aTyr, 2, Bayer, 2, 5, BMS, 2, Boehringer Ingelheim, 2, 5, Bristol-Myers Squibb, 2, Celgene, 2, 5, Galapagos, 2, 5, GlaxoSmithKline, 2, 5, Inventiva, 2, 5, JB Therapeutics, 5, medac, 5, Medac, 5, Novartis, 2, Pfizer, 5, RedX, 2, RuiYi, 5, Sanofi, 2, Sanofi-Aventis, 2, UCB, 2, 5; C. McKimmie, Capella Biosciences, 2; F. Del Galdo, AstraZeneca, 5, 8, GSK, 5, 8, Boehringer-Ingelheim, 5, 8, Actelion, 5, 8, Capella Biosciences, 2, 5, Chemomab, 2, 5.

To cite this abstract in AMA style:

Ross R, Corinaldesi C, Migneco G, El-Sherbiny Y, Holmes S, Distler J, McKimmie C, Del Galdo F. BDCA2 Targeting of Human Plasmacytoid Dendritic Cells via CBS004 Reverts Dependent IFN Activation and Tissue Fibrosis in vitro and in vivo [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/bdca2-targeting-of-human-plasmacytoid-dendritic-cells-via-cbs004-reverts-dependent-ifn-activation-and-tissue-fibrosis-in-vitro-and-in-vivo/. Accessed April 13, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/bdca2-targeting-of-human-plasmacytoid-dendritic-cells-via-cbs004-reverts-dependent-ifn-activation-and-tissue-fibrosis-in-vitro-and-in-vivo/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.